Medical/Pharmaceuticals

MedicosBiotech Wins CES 2025 Innovation Award in Digital Health

SEOUL, South Korea, Jan. 7, 2025 /PRNewswire/ -- MedicosBiotech proudly announces its recognition at CES 2025, the world's premier technology event, as a recipient of the prestigious CES Innovation Award in the Digital Health category. This award honors excellence in innovation, technology, and d...

2025-01-08 01:00 3035

Insilico Received Positive Topline Results from Two Phase 1 Trials of ISM5411, New Drug Designed Using Generative AI for the Treatment of Inflammatory Bowel Disease

* Two separate Phase I studies conducted in Australia and in China indicate that ISM5411 was generally safe and well tolerated in all dose groups, demonstrating a favorable PK profile in validating gut-restrictive properties. * Supported by Insilico's commercially-available generative AI platf...

2025-01-07 22:00 2048

Verismo Therapeutics Announces Strategic Partnership with IFLI to Support SynKIR™-310 Development in Follicular Lymphoma

* Verismo will receive up to $4.05 million USD in investments from the Institute for Follicular Lymphoma Innovation (IFLI). * The partnership with IFLI will accelerate the clinical development of SynKIR™-310 in Follicular Lymphoma (FL) by leveraging IFLI's expertise and network, expanding cli...

2025-01-07 21:00 1838

Alebund Pharmaceutical announced the 1st closing of RMB 550 million in Series C financing

SHANGHAI and YANGZHOU, China, Jan. 7, 2025 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for renal diseases and related chronic conditions, announced the closing ...

2025-01-07 21:00 2102

GORTEC Announces New Trial Success for Head and Neck Cancer Treatment

TOURS, France, Jan. 7, 2025 /PRNewswire/ -- GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, Bristol Myers Squibb's anti-PD-1 therapy, as a post-operative treatment component for resected pa...

2025-01-07 21:00 2524

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

TAMPA, Fla., Jan. 7, 2025 /PRNewswire/ -- Concept Medical Inc. , a global leader in innovative drug-delivery technology, proudly reports positive outcomes from theSIRONA (Head-to-Head Comparison ofSIROlimus versus Paclitaxel Drug-Eluting BallooN Angioplasty in th...

2025-01-07 20:14 2765

Eyebright Medical Receives NMPA Class III Certificate for its Phakic Intraocular Lens

HONG KONG, Jan. 7, 2025 /PRNewswire/ -- Eyebright Medical Technology (Beijing) Co., Ltd. ("Eyebright Medical", the "Company", Stock Code: 688050.SH, together with its subsidiaries collectively known as the "Group") is proud to announce that our Phakic intraocular lens, "Loong Crystal PR", has rec...

2025-01-07 20:07 2315

U.S. FDA Granted Priority Review to Dizal's Sunvozertinib New Drug Application

* If approved, Sunvozertinib as a single oral drug would offer a convenient and safe treatment option with superior efficacy for NSCLC patients with EGFR exon20ins * Sunvozertinib's NDA was submitted based on the multinational pivotal WU-KONG1 Part B study, the results of which were presented...

2025-01-07 18:00 2070

Weimai bags RMB200m in Series D funding to enhance tech-enabled, continuous healthcare services

The latest funding round will fuel Weimai's efforts to expand its full-cycle healthcare solutions, leveraging AI and digital tools to provide comprehensive care acrossChina HANGZHOU, China, Jan. 7, 2025 /PRNewswire/ -- Weimai, a leading provider of one-stop digital healthcare solutions inChina, ...

2025-01-07 16:19 2250

Akeso to Share Global Strategy for New Drug Development at the 43rd J.P. Morgan Healthcare Conference

HONG KONG and SAN FRANCISCO, Jan. 6, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference, taking place onJanuary 13, 2025, in San Francisco, California. The company's founder, ...

2025-01-07 11:18 2011

NUS researchers boost chemotherapy uptake in breast cancer treatment with localised magnetic fields

A recent study explained the mechanisms by which pulsed electromagnetic field therapy enhances doxorubicin uptake, paving the way for precision-driven cancer therapies with fewer side effects SINGAPORE, Jan. 6, 2025 /PRNewswire/ -- Researchers at the National University of Singapore (NUS) have d...

2025-01-07 09:33 1734

The Registrational Clinical Data of Glecirasib was Published in Nature Medicine

BEIJING, SHANGHAI and BOSTON, Jan. 6, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets announced today that the data from a registrational clinical trial of its independently developed KRAS G12C inhibitor glecirasib has been publishe...

2025-01-07 08:30 2067

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

Back to media releases Next media release LONDON, Jan. 7, 2025 /PRNewswire/ -- Nor...

2025-01-07 08:00 1667

WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager

SHANGHAI and SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO),today announced an agreement with Candid Therapeutics, Inc. ("Candid"), a clinical-stage biotechnology company focus...

2025-01-07 08:00 1934

VIV™ Ring: The World's 1st Smart Ring with Generative Sleep Aid Sound at CES 2025

* The Intuitive Smart Ring Challenging Oura and Galaxy Ring * Generative Sleep Aid Sound Enhancing Beyond Biometrics Measurement LAS VEGAS ,Jan. 6, 2025 /PRNewswire/ -- VIV Health is thrilled to announce the upcoming launch of the VIV™ Ring, the world's first smart ring equipped with Generative...

2025-01-06 23:30 2172

Datasea Announces Entry into Agreements that Will Place its Acoustic High-Tech Products in a Total of 263 Beauty Stores in Northern China

The New Agreements Projected to Generate Sales of up to 140,000 Units and $11 Million in Revenue by Year End 2025 BEIJING, Jan. 6, 2025 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS, "Datasea" or "the Company"), aNevada-based digital technology company specializing in acoustic high-tech and 5G AI m...

2025-01-06 22:45 3935

EMSRUN Medical Celebrates 15 Years of Excellence in Life-Saving Solutions

WUXI, China, Jan. 6, 2025 /PRNewswire/ -- EMSRUN Medical, a leader in tactical, pre-hospital, and civilian emergency medical solutions, marks its 15th anniversary this year. Since its establishment in 2010, the company has built an outstanding reputation for delivering critical solutions to comba...

2025-01-06 22:10 1854

Technoderma Medicines Completes Positive Ph2a Proof- of Concept Trial with Topical TDM-180935 Ointment for Atopic Dermatitis

CHENGDU, China, Jan. 6, 2025 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report the Company has completed its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ointment in patients with Atopic Dermatitis (AD). Th...

2025-01-06 21:00 1861

Concord Medical Announces Result of 2024 Annual General Meeting

BEIJING, Jan. 6, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that it held its 2024 annual general meeting of shar...

2025-01-06 20:30 3356

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

* Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritization * The Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, anddata is ...

2025-01-06 20:00 1823
1 ... 134135136137138139140 ... 646

Week's Top Stories